3 completed, 2 terminated. 3 Phase 3, 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Pegzilarginase: new trials by email Literature Review of Pegzilarginase trials Research Report on Pegzilarginase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency Pegzilarginase - Arginase 1 Deficiency | Phase 3 | Completed | Immedica Pharma AB | 3 | 2024-08-30 | 2026-05-22 |
| A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency Pegzilarginase - Arginase I Deficiency, Hyperargininemia | Phase 3 | Terminated | Aeglea Biotherapeutics | 3 | 2023-04-04 | 2023-07-27 |
| Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency Pegzilarginase, Placebo - Arginase I Deficiency, Hyperargininemia | Phase 3 | Completed | Immedica Pharma AB | 32 | 2019-05-01 | 2026-08-21 |
| Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer Pegzilarginase, Pembrolizumab - Small-cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Immedica Pharma AB | 42 | 2017-12-21 | 2026-10-28 |
| A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 Deficiency AEB1102 - Arginase I Deficiency, Hyperargininemia | Phase 2 | Completed | Immedica Pharma AB | 14 | 2017-12-07 | 2026-09-24 |
Hyperargininemia (4) · Small Cell Lung Carcinoma (1)
Immedica Pharma AB (4) · Aeglea Biotherapeutics (1)
Canada (3) · United Kingdom (3) · United States (3) · Austria (2) · Portugal (2) · France (1) · Germany (1) · Italy (1) · Puerto Rico (1)
Mattias Rudebeck, PhD MSc BMedSc (4) · Cortney Caudill (1)